ArticleDermatology and therapy2026
Patient Preferences for Treatment Attributes in Moderate to Severe Chronic Hand Eczema: A Discrete Choice Experiment.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe treatment landscape for Chronic Hand Eczema (CHE) is evolving; however, evidence on patients' preferences regarding CHE treatment attributes is sparse. This discrete choice experiment (DCE) assessed how treatment attributes influence preferences among patients with moderate to severe CHE in the USA.
methodsAdults with moderate to severe CHE recruited from an online panel completed a web-based DCE survey (August-September 2025). Seven treatment attributes, identified via literature review, qualitative patient interviews, and clinical expert input, reflected efficacy (improvements in itch, skin appearance, and pain), safety (risks of infections, cancer, and major heart problems), and administration mode/frequency. Patient preferences were analyzed using conditional logistic regression. Attributes' relative importance and willingness to trade off were calculated. Sensitivity analysis excluding participants who failed ≥ 1 validity test was conducted.
resultsOf the 300 participants with CHE included (mean age: 44.9 years; 50% female; 84.7% employed), most reported multiple CHE subtypes (70.3%). The vast majority of participants reported life impairment due to CHE, including for activities of daily living (96.3%) and work productivity (92.9%). In the DCE, all treatment attributes had a significant impact on treatment preferences (p < 0.001). Attributes with the highest relative importance were related to efficacy: itch improvement (22%) and skin appearance improvement (21%); followed by those related to safety: avoiding risk of cancer (16%) and risk of infections (14%). Other important attributes for patients included pain improvement (13%) and administration mode/frequency (7%). Participants would forgo 28.1, 11.4, and 1.3 percentage points of itch improvement probability to avoid a 1-percentage-point risk of cancer, major heart problems, and infections, respectively.
conclusionsImprovement in efficacy outcomes (itch and skin appearance) and lower risks of certain adverse events (cancer, infections) were the most important treatment attributes for patients with CHE. This study provides insights that may help support shared decision-making to ultimately improve treatment satisfaction and adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.